The nitrosoamine dephostatin interacts with nitric oxide/cGMP signalling and modulates cytosolic calcium responses in human platelets
(English)Manuscript (preprint) (Other academic)
1 The effects of the nitrosoamine dephostatin on cytosolic Ca2+ and nitric oxide (NO)/cGMP signallings in human platelets were investigated.
2 Dephostatin has been characterised as a protein tyrosine phosphatase (PTP) inhibitor, and may on that account affect platelet responses. However, western blot analysis revealed that dephostatin (1-100 µM) did not increase tyrosine-specific protein phosphorylation.
3 Dephostatin dose-dependently (0.003-3 µM) inhibited thrombin-, thrombin-receptor activating peptide-, and ADP-stimulated rises in cytosolic free Ca2+ concentration, [Ca2+]i. in fura-2-loaded platelets. Surprisingly, higher doses of dephostatin (10-30 µM) augmented thrombin-triggered Ca2+ response. This dual action of dephostatin mainly involved modulation of Ca2+ influx.
4 The results revealed that dephostatin antagonised NO/cGMP- and prostaglandin E1/cAMP-mediated inhibition of [Ca2+]1. The action of the thrornbin-neutralising peptide hirudin was, however, unaffected.
5 Dephostatin did not affect basal or NO-mediated rises in platelet cGMP content. On the other hand, dephostatin alone directly increased the phosphorylation of ser239 on vasodilator-stimulated phosphoprotein (VASP) and markedly enhanced NO/cGMP-dependent VASP phosphorylation.
6 Cell functional studies revealed that dephostatin amplified NO-induced inhibition of platelet aggregation. Opposite to that, dephostatin diminished the inhibitory action of NO on phosphatidylserine exposure.
7 In conclusion, the results revealed that dephostatin affects a wide range of mechanisms involved in Ca2+ homeostasis in platelets. These effects are apparently not due to inhibition of PTPs. However, enhancement of VASP phosphorylation represents another important molecular mechanism of dephostatin. Considering NO signalling, the results indicate that dephostatin may be an excellent tool when elucidating the relative importance of inhibition of Ca2+ versus VASP phosphorylation.
calcium, cGMP, dephostatin, nitric oxide, platelets, vasodilator-stimulated phosphoprotein
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-82119OAI: oai:DiVA.org:liu-82119DiVA: diva2:557946